Update on chronic granulomatous disease: The concept of the near-normal host

Current Clinical Topics in Infectious Diseases

Volumn , Issue 20, 2000, Pages 325-334

  Ezekowitz, R Alan B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ALGORITHM; ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TRANSPLANTATION; CHRONIC GRANULOMATOUS DISEASE; HUMAN; IMMUNOCOMPETENCE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHAGOCYTE; PHYSIOLOGY; REVIEW; SURVIVAL;

ALGORITHMS; ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TRANSPLANTATION; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; IMMUNOCOMPETENCE; INTERFERON TYPE II; NADPH OXIDASE; PHAGOCYTES; SURVIVAL ANALYSIS;

EID: 0034564267     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (37)

1. Forrest CB, Forehand JR, Axtell RA, et al. Clinical features and current management of chronic granulomatous disease. In: Curnutte JT, ed. Phagocytic defects II: abnormalities of the respiratory burst (Hematology/Oncology Clinics of North America, vol. 2, no. 2). Philadelphia: W. B. Saunders Company, 1988: 253-266.
2. Curnutte JT, Babior BM. Biological defense mechanisms: the effect of bacteria and serum on superoxide production by granulocytes. J Clin Invest 1974;53:1662-1672.
3. Clark RA, Malech HL, Gallin JI, et al. Genetic variants of chronic granulomatous disease; prevalence of deficiencies of cytosolic components of the NADPH oxidase system. N Engl J Med 1989;321:647-652.
4. Babior BM. The respiratory burst oxidase (review). Curr Opin Hematol 1995;2:55-60.
5. Meischl C, Roos D. The molecular basis of chronic granulomatous disease. Springer Semin Immunopathol 1998;19:417-434.
6. Dinaucr MC. The repiratory burst oxidase and the molecular genetics of chronic granulomatous disease. Grit Rev Clin Lab Sci 1993;30: 329-369.
7. Shatwell KP, Segal AW. NADPH oxidase. Int J Biochem Cell Biol 1996;28:1191-1195.
8. Malech HL, Maples PB, Whiting-Theobadl N, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 1997;94:12133-12138.
9. Weil WM, Linton GF, Whiting-Theobald N, et al. Genetic correction of ph67-phox deficient chronic granulomatous disease using peripheral blood progenitor cells as a target for retrovirus mediated gene transfer. Blood 1997; 89:1754-1761.
10. Schneider SD, Rusconi S, Seger RA, Hossle JP. Adenovirus-mediated gene transfer into monocyte-derived macrophages of patients with X-linked chronic granulomatous disease: ex vivo correction of deficient respiratory burst. Gene Therapy 1997;4:524-532.
11. Bjorgvinsdottir H, Ding C, Pech N, et al. Retroviral-mediated gene transfer of gp91-phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood 1997;89:41-48.
12. Dinauer MC, Ezekowitz RAB. Interferon gamma and chronic granulomatous disease. Curr Opin Immunol 1991;3:61-64.
13. Ezekowitz RAB, Dinauer MC, Jaffe HS, et al. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous Interferon gamma. N Engl J Med 1988;319:145-151.
14. International Chronic Granulomatous Disease Cooperative Study Group. A phase III study establishing efficacy of recombinant human interferon gamma for infection prophylaxis in chronic granulomatous disease. N Engl J Med 1991;324:509-516.
15. Schrenzel J, Serrander L, Banfi B, et al. Electron currents generated by the human phagocyte NADPH oxidase. Nature 1998;392: 734-737.
16. Rae J, Newburger PE, Dinauer MC, et al. X-linked chronic granulomatous disease: mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase. Am J Hum Gen 1998;62:1320-1331.
17. Gorlach A, Lee PL, Roseler J, et al. A p47-phox pseudogene carries the most common mutation causing p47-phox deficient chronic granulomatous disease. J Clin Invest 1997;100: 1907-1918.
18. Leusen JH, de Klein A, Hilarius PM, et al. Disturbed interaction of p21-rac with mutated p67-phox causes chronic granulomatous disease. J Exp Med 1996;184:1243-1249.
19. Hume DA, Gordon S. The mononuclear phagocyte system of the mouse defined immunohistochemical localization of the antigen F4/80. In: vanFurth R, ed. Mononuclear phagoytes: characteristics, physiology and function. Dordrecht: Martinus-Nijhoff, 1985:9-17.
20. Nathan C. Macrophage secretion. J Clin Invest 1987;79:319-322.
21. Ezekowitz RAB, Hoffmann J. Innate immunity: the blossoming of innate immunity (editorial overview). Curr Opin Immunol 1998;10: 9-11.
22. Foster CB, Lehmbecher T, Mol F, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 1998;102:2146-2155.
23. Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease (review). Medicine 1998;77:345-354.
24. Barton LL, Moussa SL, Villar RG, Hulett RL. Gastrointenstinal complications of chronic granulomatous disease: case report and literature review (review). Clin Pediatr 1998;37: 231-236.
25. Newburger PE, Luscinskas FW, Ryan T, et al. Variant chronic granulomatous disease: modulation of the neutrophil defect by severe infection. Blood 1986;68:914-919.
26. Royer-Pokora B, Kunkel LM, Monaco AP, et al. Cloning the gene for an inherited human disorder-chronic granulomatous disease - on the basis of its chromosomal location. Nature 1986;322:32-38.
27. Nathan CF, Kaplan G, Levis W, et al. Local and systemic effects of intradermal recombinant interferon gamma in patients with lepromatous leprosy. N Engl J Med 1986;315:6-15.
28. Ezekowitz RAB. Chronic granulomatous disease: an update and a paradigm for the use of interferon gamma as adjunct immunotherapy in infections diseases. In: Russell SW, Gordon S, eds. Macrophage biology and activation. Berlin: Springer-Verlag, 1992:283-292.
29. Kourtis AP, Abramowsky C, Ibegbu C, Kobrynski L. Enlargement of the thymus in a child with chronic granulomatous disease receiving interferon gamma therapy. Arch Pathol Lab Med 1998;122:562-565.
30. van't Hek LG, Verweij PE, Weemaes CM, et al. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Rep Crit Care Med 1998;157: 1694-1696.
31. Suzuki S, Kumatori A, Haagen IA, et al. PU. as an essential activator for the expression of gp91(phox) gene in human peripheral neutrophils, monocytes and B lymphocytes. Proc Natl Acad Sci USA 1998;95:6085-6090.
32. Dickinson RP, Bell AS, Hitchcock S, et al. Novel anti-fungal 2-aryl-1-(1H-2,4-triazol-1-YL) butan-2-OL derivates with high activity against Aspergillus fumigatus. Bioorg Med Chem Ltt 1996;16:2031-2036.
33. Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997;41:696-698.
34. Denning DW, Del Favero A, Gluckman E, et al. UK-109,496, a novel wide-spectrum triazole derivate for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis. Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiologists, 1996;F80:126.
35. Ho CM, Vowels MR, Lockwood L, Ziegler JB. Successful bone marrow transplantation in a child with X-linked chronic granulomatous disease (review). Bone Marrow Tranplantation 1996;18:213-215.
36. Ozsahin H, von Planta M, Muller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 1998;92: 2719-2724.
37. Schapiro BL, Newburger PE, Klempner MS, Dinauer MC. Chronic granulomatous disease presenting in a 69-year-old man. N Engl J Med 1991;325:1786-1790.